StockData
Contineum Therapeutics, Inc. logo

Contineum Therapeutics, Inc. (CTNM) stock

CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$9.55−0.12 (-1.24%)

Close on Nov 17, 2026Market cap $359.28MP/E –Yield –

Contineum Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Contineum Therapeutics's price to sales ratio was 0.7× on Apr 30, 2024.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Apr 30, 20240.7×–

More Contineum Therapeutics figures

See a number that looks wrong?